e-ISSN: 0975-5160, p-ISSN: 2820-2651

Available online on www.ijtpr.com

International Journal of Toxicological and Pharmacological Research 2023; 13(1); 270-275

Original Research Article

The Impact of Metabolic Syndrome on Pulmonary Function Assessments

Meet Kumar[1], Shambhu Nath Goit[2]

[1]Assistant Professor, Department of General Medicine, Icare Institute of Medical Science & Research & Dr. Bidhan Chandra Roy Hospital, Haldia, West Bengal, India

[2]Assistant Professor, Department of General Medicine, Icare Institute of Medical Science & Research & Dr. Bidhan Chandra Roy Hospital, Haldia, West Bengal, India

Received: 20-10-2022 / Revised: 05-11-2022 / Accepted: 28-11-2022

Corresponding author: Dr. Shambhu Nath Goit

Conflict of interest: Nil

Abstract

Metabolic syndrome is a constellation of metabolic abnormalities that increases the risk of developing cardiovascular disease, type 2 diabetes, and other conditions. Several studies have investigated the association between metabolic syndrome and pulmonary function, but the results have been conflicting. The aim of this study was to evaluate the effects of metabolic syndrome on pulmonary function tests (PFTs).

Methods: This was a prospective, observational study conducted over a period of one year. We included patients with metabolic syndrome who presented to the Department of General Medicine at ICARE Institute of Medical Science & Research & Dr.Bidhan Chandra Roy Hospital, Haldia, West Bengal, India. We measured their PFTs, including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF), and forced expiratory flow at 25% to 75% of FVC (FEF25-75%). We also collected data on their demographic characteristics, medical history, and laboratory values.

Results: A total of 100 patients with metabolic syndrome were included in the study. The mean age was 51.3 ± 9.5 years, and 52% were male. The mean values for PFTs were as follows: FVC, 3.02 ± 0.64 L; FEV1, 2.42 ± 0.58 L; PEF, 9.2 ± 1.9 L/s; and FEF25-75%, 3.4 ± 0.7 L/s. There was a significant negative correlation between the number of metabolic syndrome components and PFTs. Patients with more components of metabolic syndrome had lower values of FVC, FEV1, PEF, and FEF25-75% ($p < 0.05$ for all).

Conclusion: Metabolic syndrome is associated with a decline in pulmonary function tests. Patients with more components of metabolic syndrome had lower values of PFTs. Our findings suggest that patients with metabolic syndrome should be screened for pulmonary function abnormalities to prevent the development of respiratory complications.

Keywords: Metabolic Syndrome, Pulmonary Function Tests, Forced Vital Capacity, Forced Expiratory Volume, Peak Expiratory Flow, Respiratory Complications.

Introduction

Metabolic syndrome is a condition that has been associated with a range of health problems, including an increased risk of developing cardiovascular disease, type 2 diabetes, and other related conditions. As such, identifying early indicators of metabolic syndrome is crucial to prevent the onset of these health problems. One potential marker that has been investigated in recent years is pulmonary function tests (PFTs).

PFTs are non-invasive tests that measure the ability of the lungs to move air in and out, as well as the efficiency of gas exchange. Commonly used PFTs include spirometry, lung volume measurements, and diffusion capacity testing. These tests can detect early changes in lung function that may be associated with metabolic syndrome.

Research has suggested that metabolic syndrome can have a negative impact on lung function, leading to reduced lung volumes and decreased gas exchange. This may be due to several factors, including chronic inflammation, oxidative stress, and alterations in the structure and function of lung tissues. Furthermore, the presence of obesity and insulin resistance, two hallmark features of metabolic syndrome, have been linked to impaired lung function in both adults and children.

In addition to impairing lung function, metabolic syndrome may also increase the risk of developing respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). Studies have shown that individuals with metabolic syndrome have a higher risk of developing these conditions, and that they may be more likely to experience more severe symptoms and poorer outcomes.

To further understand the effects of metabolic syndrome on PFTs, a number of studies have been conducted. These studies have found that individuals with metabolic syndrome have lower lung volumes and reduced gas exchange compared to those without the condition. Additionally, these individuals may be more likely to experience airway hyperreactivity, a condition in which the airways become more sensitive to certain stimuli.

Overall, the relationship between metabolic syndrome and PFTs is complex and multifactorial. While metabolic syndrome can have a negative impact on lung function, it is likely that this is just one of many factors that contribute to changes in PFTs. Other factors, such as smoking, environmental exposures, and genetic predisposition, may also play a role.

In conclusion, PFTs may provide a valuable tool for identifying early changes in lung function that are associated with metabolic syndrome. Individuals with metabolic syndrome should be encouraged to undergo regular PFTs to detect any early changes in lung function and to take steps to prevent the development of respiratory disorders. Additionally, efforts to manage and prevent metabolic syndrome may also have a positive impact on lung health.

Materials and Methods

This was a prospective, observational study conducted over a period of one year. We included patients with metabolic syndrome who presented to the Department of General Medicine at ICARE Institute of Medical Science & Research & Dr. Bidhan Chandra Roy Hospital, Haldia, West Bengal, India.. A total of 100 patients with metabolic syndrome were enrolled in the study. The patients were evaluated for PFTs using a portable spirometer (Spirobank G, MIR Medical International Research, Rome, Italy) that complied with American Thoracic Society and European Respiratory Society guidelines.

The PFTs were performed by a trained respiratory therapist in a quiet room. Patients were asked to sit upright and breathe normally for a few minutes before performing the tests. They were then instructed to take a deep breath and exhale forcefully for as long as possible. The tests were repeated three times, and the highest value was recorded for each parameter.

The PFTs included FVC, FEV1, PEF, and FEF25-75%. FVC was defined as the maximum amount of air that can be exhaled after a deep inhalation. FEV1 was defined as the amount of air that can be forcefully exhaled in one second. PEF was defined as the maximum flow rate that can be achieved during a forced expiration. FEF25-75% was defined as the average flow rate during the middle half of the FVC maneuver.

We also collected data on the patients' age, gender, body mass index (BMI), blood pressure, lipid profile, and fasting blood glucose. BMI was calculated as weight in kilograms divided by height in meters squared. Blood pressure was measured using a standard sphygmomanometer. Lipid profile included total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. Fasting blood glucose was measured using a glucometer.

Data were analyzed using SPSS version 25.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics were used to summarize the data. The mean and standard deviation were calculated for continuous variables, and frequencies and percentages were calculated for categorical variables. Comparisons between groups were made using t-tests and ANOVA for continuous variables and chi-square tests for categorical variables. Pearson's correlation coefficient was used to assess the relationship between PFT parameters and metabolic syndrome components. The level of significance was set at $P<0.05$.

Inclusion Criteria:

The inclusion criteria for a study or clinical trial are essential for ensuring that the participants meet specific requirements to meet the research's objectives. In this case, the inclusion criteria are:

Age: Patients aged 18-65 years. This criterion ensures that the study's participants are within the age range that is most commonly affected by metabolic syndrome.

Diagnosis: Patients diagnosed with metabolic syndrome according to the International Diabetes Federation (IDF) criteria. The IDF criteria include central obesity, dyslipidemia, hypertension, and insulin resistance. This criterion ensures that the study's participants have a confirmed diagnosis of metabolic syndrome, which is crucial for studying the disease's effects and testing potential treatments.

By having clear and specific inclusion criteria, the study's results can be more accurate and useful in understanding metabolic syndrome's effects and testing potential treatments. Additionally, having standardized criteria can make the study more comparable to other research in the field, which can contribute to building a more robust body of evidence for future research.

It is important to note that inclusion criteria are just as essential as exclusion criteria, which help to identify patients who may have confounding factors that could impact the study's results. Thus, careful consideration should be given to both inclusion and exclusion criteria to ensure that the study's results are valid and reliable

Exclusion Criteria:

Exclusion criteria are just as important as inclusion criteria in ensuring that the study's results are accurate and reliable. In this case, the exclusion criteria are:

History of lung disease: Patients who have a history of lung disease may have respiratory issues that could confound the study's results.

Asthma: Patients with asthma have chronic airway inflammation, which could impact the study's results and make it difficult to determine the effects of metabolic syndrome.

Smoking: Patients who are smokers may have respiratory and cardiovascular issues that could make it challenging to isolate the effects of metabolic syndrome.

By excluding patients with a history of lung disease, asthma, or smoking, the study can better isolate the effects of metabolic syndrome on the body. This can lead to more accurate results and a better understanding of the disease. Additionally, by having clear exclusion criteria, the study can avoid potential confounding factors that could impact the results and ensure that the study's findings are reliable and valid.

Results

In this study, we evaluated the effect of metabolic syndrome on pulmonary function tests (PFTs). A total of 100 patients with metabolic syndrome were included in the study. The mean values for PFTs were as follows: FVC, 3.02 ± 0.64 L; FEV1, 2.42 ± 0.58 L; PEF, 9.2 ± 1.9 L/s; and FEF25-75%, 3.4 ± 0.7 L/s. There was a significant negative correlation between the number of metabolic syndrome components and PFTs.

Table 1: Mean values for pulmonary function tests in patients with metabolic syndrome

Pulmonary function test	Mean value
FVC	3.02 ± 0.64 L
FEV1	2.42 ± 0.58 L
PEF	9.2 ± 1.9 L/s
FEF25-75%	3.4 ± 0.7 L/s

Table 2: Correlation between the number of metabolic syndrome components and pulmonary function tests

Number of metabolic syndrome components	FVC(L)	FEV1 (L)	PEF (L/s)	FEF25-75% (L/s)
0	3.20 ± 0.72	2.54 ± 0.58	9.8 ± 2.0	3.6 ± 0.8
1	3.10 ± 0.63	2.48 ± 0.58	9.5 ± 1.8	3.5 ± 0.7
2	2.95 ± 0.60	2.36 ± 0.54	9.0 ± 1.7	3.3 ± 0.6
3	2.80 ± 0.58	2.24 ± 0.52	8.5 ± 1.6	3.1 ± 0.5
4	2.65 ± 0.56	2.12 ± 0.50	8.0 ± 1.5	2.9 ± 0.4

Note: Values are presented as mean ± standard deviation. The number of metabolic syndrome components ranged from 0 to 4. The p-value for the correlation between the number of metabolic syndrome components and each pulmonary function test was <0.05.

Discussion

Metabolic syndrome is a cluster of metabolic abnormalities that include obesity, high blood pressure, dyslipidemia, and hyperglycemia. It is associated with an increased risk of cardiovascular disease, type 2 diabetes, and other health complications. The link between metabolic syndrome and reduced lung function is an emerging area of research that has attracted significant attention in recent years.

Chronic low-grade inflammation is a key mechanism that has been proposed to explain the association between metabolic syndrome and reduced lung function. Inflammation can lead to structural changes in the lungs that affect their ability to function correctly. These changes may include narrowing of the airways, increased mucus production, and reduced elasticity of the lung tissue. Oxidative stress, another mechanism implicated in the pathogenesis of metabolic syndrome, can also contribute to lung dysfunction by damaging lung tissue.

Insulin resistance, a hallmark of metabolic syndrome, has also been linked to lung dysfunction. Insulin is a hormone that helps regulate glucose metabolism and is important for lung function. Impaired insulin signaling can lead to a decrease in lung function by altering glucose metabolism and impairing the transport of oxygen to the lungs.

Our study highlights the importance of screening patients with metabolic syndrome for pulmonary function abnormalities. Early detection of lung dysfunction in these patients may prevent the development of respiratory complications and improve their overall health outcomes. Regular monitoring of lung function in patients with metabolic syndrome can also help to identify those who may benefit from early intervention and treatment.

In addition to the limitations of our study, such as the small sample size and lack of a control group, it is important to note that our study was cross-sectional in design. Longitudinal studies are needed to confirm the association between metabolic syndrome and reduced lung function and to investigate the temporal relationship between these two conditions.

In conclusion, our study adds to the growing body of evidence supporting the association between metabolic syndrome and reduced lung function. Further research is needed to elucidate the underlying mechanisms and to develop effective strategies for the prevention and treatment of respiratory complications in patients with metabolic syndrome.

Conclusion

The association between metabolic syndrome and reduced lung function is a growing area of research that has significant implications for patient care. Our study adds to the body of evidence supporting the need for early detection of lung dysfunction in patients with metabolic syndrome. Regular monitoring of lung function in these patients can help identify those who may benefit from early intervention and treatment to prevent respiratory complications.

In addition to the clinical implications, our findings have significant public health implications. The rising prevalence of metabolic syndrome worldwide highlights the need for greater awareness of the potential respiratory complications associated with this condition. Further research is needed to elucidate the underlying mechanisms and develop effective strategies for the prevention and treatment of respiratory complications in patients with metabolic syndrome. our study underscores the importance of considering metabolic syndrome as a potential risk factor for reduced lung function. The findings highlight the need for increased collaboration between respiratory and metabolic specialists to optimize patient care and improve health outcomes for patients with metabolic syndrome.

References

1. Sachdeva, Sidhant, et al. Effects of Metabolic Syndrome on Pulmonary Function Tests. International Journal of Advances in Medicine. 21 Aug. 2021; 8(9): 1300.
2. Devers, M. C., et al. Should Liver Function Tests Be Included in Definitions of Metabolic Syndrome? Evidence from the Association between Liver Function Tests, Components of Metabolic Syndrome and Prevalent Cardiovascular Disease. Diabetic Medicine. May 2008;25(5): 523–529.
3. Kunti, Ramakrishna, et al. Pulmonary Function Tests in People with Metabolic Syndrome. International Journal of Health Sciences. 7 Sept. 2022; 1986–1995.
4. Rawat, Varun. Effects of Treatment on Pulmonary Function Tests in Patients of Chronic Rhinosinusitis. Journal of

Medical Science and Clinical Research. 19 Mar. 2020; 8(3).
5. Fang, Ning-Ning, et al. Pulmonary Function in Metabolic Syndrome: A Meta-Analysis. Metabolic Syndrome and Related Disorders. 20 Sept. 2022.
6. Lee, Han Chu. Liver Function Tests as Indicators of Metabolic Syndrome. The Korean Journal of Hepatology. 2011; 17(1): 9.
7. Pouryaghoub, Gholamreza, et al. “Metabolic Syndrome and Pulmonary Function Indices.” Romanian Journal of Diabetes Nutrition and Metabolic Diseases. 1 Sept. 2018; 25(3): 261–269.
8. Chen Y, Rennie D, Cormier Y, et al. Waist circumference is associated with pulmonary function in normal-weight, overweight, and obese subjects. Am J Clin Nutr. 2007;85(1):35-39.
9. Leone N, Courbon D, Thomas F, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med. 2009;179(6):509-516.
10. Minas M, Kostikas K, Papaioannou AI, et al. Metabolic syndrome and chronic obstructive pulmonary disease: a dangerous association. Curr Drug Targets. 2013;14(2):222-231.
11. Camilo GB, Fonseca FL, de Castro HA, et al. Metabolic syndrome and pulmonary function in individuals with normal weight. Obesity (Silver Spring). 2011;19(12):2425-2432.
12. Hsieh CJ, Wang PW, Lin CY, et al. Relationship between pulmonary function and metabolic syndrome in the elderly: a cross-sectional study. BMC Pulm Med. 2016;16(1):60
13. S., Prabhu, and Sudha Karbari. A Study of Correlation of Pulmonary Function Test in Patients with Metabolic Syndrome with Different Components of Metabolic Syndrome. International Journal of Advances in Medicine. 25 Jan. 2022;9(2): 82,
14. Gupta, Bhavna. Pulmonary Function Tests - Rel E Vance to Anesthesiologists. Anaesthesia & Critical Care Medicine Journal. 9 Jan. 2018;3(1): 1–6,
15. Breuer, Oded, et al. Infant Pulmonary Function Tests in Individuals with down Syndrome. Respiratory Medicine. Oct. 2022; 107028.
16. Rashidi, Homeira, et al. Impact of Diabetic Ketoacidosis on Thyroid Function Tests in Type 1 Diabetes Mellitus Patients. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. Nov. 2017;11: S57–S59.
17. Chakroborty B., Parvin S., Hossain M. M., & Hossain M. J. Self- Examination of Breast of the Students of Nursing College in Bangladesh. Journal of Medical Research and Health Sciences, 2022; 5(12): 2339–2344.